San Francisco / Oxford / Portland / St. Louis / Rochester / Seattle / Phoenix / Dallas / Buffalo / Montreal / Cleveland / Baltimore / New York / New Haven / /
Company
Synarc Inc. / Acorda Therapeutics Inc. / XenoPort Inc. / TE AE / Vaccinex / Glycominds Inc. / Rho Inc. / Gd / Eisai Inc. / EMD Serono Inc. / Pfizer Inc / Glycominds Ltd. / Multiple Sclerosis Collaborative Research Group / Gerson Lehrman Group / aan.com / Shire plc / Therapeutic Advances / Avanir Pharmaceuticals / Cyberonics Inc. / Bayhill Therapeutics / BioMS Medical / Novo Nordisk / DioGenix Inc. / Biomarin / AEs / Abbott / Eli Lilly and Company / Karvigh SA / Elan Corporation / NIH/NIAID / Biogen Idec / Metabolic Solutions Development Co. / Athena Diagnostics Inc. / Journal of Neuroimmunology / Brain Pathology / Bayer Schering Pharma / ITN / Actelion Pharmaceuticals Ltd / Relavesio Inc. / IMPAX Laboratories Inc. / Neurotherapeutics / Coronado BioSciences / Novartis / Takeda Pharmaceutical Company Limited / AAN Enterprises Inc. / CNS Imaging Consultant LLC / Roche / GlaxoSmithKline / Neurology / Genentech Inc. / GLOSSARY AE / Wyeth / Archives / Ono Pharmaceutical Co. Ltd. / Merck Serono / Multiple Sclerosis International / Genzyme Corporation / Continuum / Guidepoint Global LLC / Vertex Pharmaceuticals / NMO Research / Accelerated Cure Project / Daiichi Sankyo / Teva Pharmaceutical Industries Ltd. / /
Country
United Kingdom / Canada / United States / / /
Event
Funding / Business Partnership / Person Communication and Meetings / M&A / /
Facility
Science University / University of California / University of Rochester / Montreal Neurological Institute / National Institute of Allergy / Jacobs Neurological Institute / Johns Hopkins University / Clinic Foundation / Barrow Neurological Institute / University of Texas / ICTS Washington University / Washington University / National Cancer Institute / University of Southern California / Southwestern Medical Center / Chapel Hill / /
IndustryTerm
as MS therapy / literature search / secondary imaging endpoints / imaging / treatment of MS / clinical and imaging effects / Multiple Sclerosis Therapeutics / placebo / MS therapy / atorvastatin / /
Doris Duke Charitable Foundation / University of California / Guthy Jackson Greater Good Foundation / Maisin Foundation / Nancy Davis Center / Nancy Davis Foundation / Montreal Neurological Institute / National MS Society / University of Rochester / National Institute of Allergy and Infectious Diseases / Guthy Jackson Charitable Foundation / Washington University / National Cancer Institute / Jacobs Neurological Institute / Rocky Mountain Multiple Sclerosis Society / Virginia Mason MS Center / Johns Hopkins University / Oregon Health & Science University / National MS Society USA / Barnes-Jewish Hospital Foundation / Keck School of Medicine / Montel Williams Foundation / Sinai School of Medicine / Cleveland Clinic Foundation / Southwestern Medical Center / University of Texas / National Institute of Health / Yale / University of Southern California / Los Angeles / National Multiple Sclerosis Society / Barrow Neurological Institute / US Department of Veterans Affairs / Medicine MS Center / /
Person
D. Ikle / E. Waubant / S.S. Zamvil / M. Kita / A. Cross / Cross serves / A. Goodman / Virginia Mason / A. Bar-Or / J.A. Cohen / N. Kachuck / B. Weinstock-Guttman / P.A. Calabresi / Alan Evangelista / J. Preiningerova / Gary Cutter / Daniel Pelletier / Pelletier serves / D. Pelletier / S. Murphy / O. Stu¨ve / H. Kopetskie L. Ding / S. Schwid / Okuda / A. Miller / Chelsea Therapeutics / M. Mass / O. Stu / T. Vollmer / M. Mokhtarani / M. Racke / /
Position
site pharmacist / masked statistician / Author / using Fisher / Editor / project coordinator / speaker / consultant / Neurologist / Prime Minister / study coordinator / received speaker / pharmacist / Consulting Editor / Director / Fisher / /
Randomized controlled trial of atorvastatin in clinically isolated syndrome The STAyCIS study E. Waubant, MD, PhD D. Pelletier, MD